Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
The FDA approved Viridian Therapeutics' Lumvoa for the treatment of thyroid eye disease, marking the company's first commercial product launch. Approval was supported by data from the THRIVE and THRIVE-2 pivotal Phase 3 trials, which demonstrated rapid and consistent reductions in proptosis and diplopia across both active and chronic patient populations.
Key figures
- Drug Name
- Lumvoa (veligrotug-vvze)
- Phase Of Trial
- Phase 3
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.